Related Experiment Video
Updated: Feb 10, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Development of targeted therapy and immunotherapy for treatment of small cell lung cancer
Motonobu Saito1,2,3, Kouya Shiraishi1, Akiteru Goto4
1Division of Genome Biology, National Cancer Center Research Institute, Tokyo.
Abstract:
Targeted therapy against druggable genetic aberrations has shown a significantly positive response rate and longer survival in various cancers, including lung cancer. In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy. On the other hand, targeted therapy against driver gene aberrations has not been adapted yet in small cell lung cancer (SCLC). This is because driver genes and druggable aberrations are rarely identified by next generation sequencing in SCLC. Recent advances in the understanding of molecular biology have revealed several candidate therapeutic targets. To date, poly [ADP-ribose] polymerase (PARP), enhancer of zeste homologue 2 (EZH2) or delta-like canonical Notch ligand 3 (DLL3) are considered to be druggable targets in SCLC. In addition, another candidate of personalized therapy for SCLC is immune blockade therapy of programmed death-1 (PD-1) and its ligand, PD-L1. PD-1/PD-L1 blockade therapy is not a standard therapy for SCLC, so many clinical trials have been performed to investigate its efficacy. Herein, we review gene aberrations exploring the utility of targeted therapy and discuss blockade of immune checkpoints therapy in SCLC.
Insights
Targeted therapies are effective in lung adenocarcinoma but not yet in small cell lung cancer due to rare driver gene identification. New targets like PARP, EZH2, DLL3, and PD-1/PD-L1 blockade show promise for SCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapy improves outcomes in lung adenocarcinoma (LADC) by targeting EGFR mutations and ALK fusions.
- Small cell lung cancer (SCLC) lacks standard targeted therapies due to infrequent identification of driver gene aberrations via next-generation sequencing.
Purpose of the Study:
- To review potential gene aberrations for targeted therapy in SCLC.
- To discuss the utility of immune checkpoint blockade therapy in SCLC.
Main Methods:
- Review of current literature on SCLC molecular biology and therapeutic targets.
- Analysis of identified druggable targets including PARP, EZH2, DLL3, and PD-1/PD-L1.
Main Results:
- Several candidate druggable targets, including PARP, EZH2, and DLL3, have been identified for SCLC.
- Immune checkpoint blockade targeting PD-1/PD-L1 is under investigation through numerous clinical trials for SCLC efficacy.
Conclusions:
- Advances in molecular understanding reveal potential targeted therapies for SCLC.
- Further research and clinical trials are crucial to establish targeted and immune blockade therapies as standard treatments for SCLC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Tumor Immunotherapy
Gene Therapy
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

